![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
Sciele a Buy Since January - Zacks Tale of the Tape
Zacks Market Commentaries (September 2nd, 2008) Writes:
Those of who took note of Zacks senior biotech analyst Jason Napodano, CFA's upgrade to a Buy recommendation for Sciele Pharmaceuticals (SCRX) early this year will be happy to know the company has just been sold to Shionogi & Co., a Japanese firm, for $1.4 billion in cash. Shares of SCRX were up about 60% as of today's opening. Price appreciation has skyrocketed to around $30.58 per share.
It helps that this comes of a day with positive momentum for the stock market as the price of oil has again come down. Nevertheless, congratulations to all who took Jason's advice, when shares were trading at under $19 per share he said, "We believe the current share price represents an attractive entry point for long-term investors and we rate the stock a Buy."
We await an updated report on SCRX in the days to come. But the buyout also reaffirms the industry
...Grant Zeng, interview, Jason Napodano, Oil, Sciele Pharmaceuticals, Shionogi & Co., Stocks to Watch, USD
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.